ALK vs BLTE: How Alaska Air Group and Belite Bio, Inc Compare (2026)
Last updated August 2026
Short answer
ALK and BLTE are similarly sized, but ALK trades noticeably cheaper on forward earnings (7.93x vs 169.64x): the market is paying up for BLTE's profile and pricing ALK more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
ALK vs BLTE: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ALK | BLTE | What it tells you |
|---|---|---|---|
| Market cap | $5.29B | $6.44B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 7.93 | 169.64 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.28 | -1.23 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 44% of range | 72% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.44 | 7.94 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: ALK is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ALK and BLTE affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALK and BLTE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALK and BLTE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Alaska Air Group (ALK) do?
Alaska Air Group operates Alaska Airlines, Hawaiian Airlines, and regional carrier Horizon Air, flying passengers primarily across the US West Coast, Hawaii, and expanding transpacific and long-haul routes. The company closed its roughly $1.9 billion acquisition of Hawaiian Airlines in September 2024 and reached a single operating certificate for the two carriers during 2025, and it runs a large loyalty and co-branded credit card franchise on top of the flying business.
What does Belite Bio, Inc (BLTE) do?
Belite Bio is a San Diego-based, Cayman-incorporated drug developer with roughly 41 employees and one molecule that matters: tinlarebant (also known as LBS-008), a once-daily oral antagonist of retinol binding protein 4 (RBP4). RBP4 is the sole carrier that ferries vitamin A from the liver to the eye, and in certain retinal diseases that vitamin A turns into toxic byproducts called bisretinoids that kill retinal cells. Tinlarebant turns the supply down without shutting off vitamin A to the rest of the body. The lead indication is Stargardt disease type 1 (STGD1), a monogenic ABCA4 disorder affecting an estimated 53,000 people in the United States with no approved treatment at all. The pivotal Phase 3 DRAGON trial enrolled 104 adolescent patients and reported a 35.7% reduction in the annualized growth rate of macular lesions versus placebo (p=0.0033) in December 2025. Tinlarebant carries Breakthrough Therapy, Fast Track and Rare Pediatric Disease designations in the United States, Orphan Drug Designation in the United States, Europe, Japan and Switzerland, and Sakigake designation in Japan. The rolling NDA began in April 2026 and was completed on June 12, 2026.
ALK vs BLTE: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ALK drivers: Hawaiian merger synergies; Loyalty and premium revenue.
- BLTE drivers: The FDA decision on tinlarebant in Stargardt disease; A small, genetically findable patient population.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Airlines are highly cyclical and capital intensive, so a slowdown in travel demand or a recession can quickly turn thin margins into losses. For BLTE, this is a one-molecule company, so an FDA setback on tinlarebant would take most of the equity story with it.
ALK or BLTE: which should you pick?
ALK vs BLTE: the full fundamentals
ALK. Revenue jumped in 2025 mainly because Hawaiian Airlines was consolidated for a full year, but profitability stayed thin and the first quarter of 2026 swung to a GAAP loss on higher fuel and one-time disruptions. Management suspended full-year 2026 guidance citing fuel price volatility. Investors are valuing the stock largely on expected merger synergies and a normalization of margins rather than on current trailing earnings.
BLTE. There is no earnings multiple here, because there are no earnings and no revenue to anchor one. The market is pricing a probability-weighted view of a Stargardt approval, an orphan launch into roughly 53,000 identifiable US patients, and a free option on geographic atrophy, and at about $5.7 billion of enterprise value that arithmetic requires most of those pieces to work. Analyst price targets published in the summer of 2026 cluster around $210, roughly 30% above the August level, which tells you the analyst consensus assumes approval rather than debating it.
Headline figures (approximate, JULY 2026): ALK shows revenue (fy2025) ~$14.2B, revenue growth (2025 vs 2024) ~+21%, fy2025 gaap eps ~$0.18, fy2025 adjusted eps ~$0.43; BLTE shows product revenue None (no approved product), cash, equivalents and treasuries ~$798.6 million as of March 31, 2026, net loss (q1 2026) ~$26.9 million GAAP, ~$13.7 million excluding share-based compensation, r&d expense (q1 2026) ~$15.7 million, up from ~$9.4 million a year earlier.
The bottom line: ALK vs BLTE
ALK and BLTE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALK and BLTE exposure against your real portfolio. It is not an investment adviser.
Wondering how ALK or BLTE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Alaska Air Group with AI
Connect the broker you already use and ask Walnut's AI how ALK fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between ALK and BLTE?
+
Alaska Air Group operates Alaska Airlines, Hawaiian Airlines, and regional carrier Horizon Air, flying passengers primarily across the US West Coast, Hawaii, and expanding transpacific and long-haul routes. Belite Bio is a San Diego-based, Cayman-incorporated drug developer with roughly 41 employees and one molecule that matters: tinlarebant (also known as LBS-008), a once-daily oral antagonist of retinol binding protein 4 (RBP4). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ALK or BLTE the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ALK or BLTE?
+
On forward P/E (as of August 2026), ALK trades at 7.93x and BLTE at 169.64x, so ALK is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ALK and BLTE?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ALK vs BLTE?
+
ALK: Airlines are highly cyclical and capital intensive, so a slowdown in travel demand or a recession can quickly turn thin margins into losses. Fuel price volatility is severe enough that Alaska suspended full-year 2026 guidance, and a spike directly compresses profitability. Merger integration carries execution risk, including labor harmonization, operational disruptions like those that hit Hawaii and Puerto Vallarta in early 2026, and the chance that synergy targets slip. The company also carries acquisition-related debt, and airlines broadly face labor cost inflation, weather and IT operational risk, and regulatory scrutiny. BLTE: This is a one-molecule company, so an FDA setback on tinlarebant would take most of the equity story with it. The DRAGON primary endpoint was anatomic, the growth rate of atrophic lesions measured on autofluorescence imaging, rather than a demonstrated improvement in what patients can actually see, and the trial ran in 104 adolescents, so how a regulator and later a payer weigh that surrogate is not settled. The mechanism deliberately restricts vitamin A delivery to the eye, and the observed side effects follow from that: xanthopsia (yellow-tinged vision), delayed dark adaptation and night vision impairment were the most common drug-related ocular events, which is a meaningful question for a chronic therapy started in adolescence. At roughly $6.3 billion of market value with no revenue, the price already embeds both approval and some value for the geographic atrophy option, so the asymmetry is not obviously favorable at either outcome. Share count rose about 14% year over year through repeated offerings, roughly 42.8% of the company is held by a single shareholder (Lin Bioscience International Ltd.), the ADS structure and foreign private issuer status mean reporting on Form 20-F and 6-K rather than 10-K and 10-Q, and short interest sits near 6.3% of shares outstanding against a company that devotes an explicit risk factor in its annual report to bearish research campaigns.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ALK or BLTE; figures are approximate and dated (as of August 2026). Verify current data before investing.